Only 27 million imatinib was sold

1.

According to the announcement, Sinopharm Yixin Pharmaceutical Co.

The announcement stated that the company's imatinib mesylate tablets had passed the generic drug quality and efficacy consistency evaluation in May 2021

Shanghai Modern Pharmaceutical stated that after the signing of this contract, Sinopharm Yixin still needs to complete the change of the relevant preparation marketing license holder, and will implement the transfer of raw material technology and the change of preparation production address.

2.

Public information shows that in the 4+7 volume procurement negotiations, Hausen’s imatinib mesylate tablets (0.

In fact, the price of imatinib mesylate tablets has been adjusted in recent years

According to data from Minai.

3.

According to the announcement, this time Sinopharm's single-minded transfer of imatinib mesylate-related technical projects is in line with the company's strategic development plan, which will help enrich the company's product battles in the field of anti-tumor and immunotherapy, and enhance Sinopharm Yixin's market competitiveness

According to data from Zhongkang, the size of China's anti-tumor drug market in 2018 was 106.

According to data released by the National Cancer Center in February 2018, the estimated number of new cases of malignant tumors in China is 3.

Earlier, the state issued policies to support the development of anti-tumor drugs

In fact, the field of anti-tumor drugs has always been the focus of innovative drug companies' research and development.
In 2018, Hengrui ranked first with 29 trials
.
With huge market demand and favorable policies, major pharmaceutical companies are actively deploying their oncology drug pipelines
.